127 related articles for article (PubMed ID: 8697438)
21. Lack of interference of DNA single-strand breaks with the measurement of double-strand breaks in mammalian cells using the neutral filter elution assay.
Johnston PJ; Bryant PE
Nucleic Acids Res; 1991 May; 19(10):2735-8. PubMed ID: 1645864
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of a genotoxicity test measuring DNA-strand breaks in mouse lymphoma cells by alkaline unwinding and hydroxyapatite elution.
Garberg P; Akerblom EL; Bolcsfoldi G
Mutat Res; 1988 Jun; 203(3):155-76. PubMed ID: 2836728
[TBL] [Abstract][Full Text] [Related]
23. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
24. Quantification of single-strand DNA lesions caused by the topoisomerase II poison etoposide using single DNA molecule imaging.
Singh V; Johansson P; Ekedahl E; Lin YL; Hammarsten O; Westerlund F
Biochem Biophys Res Commun; 2022 Feb; 594():57-62. PubMed ID: 35074586
[TBL] [Abstract][Full Text] [Related]
25. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
Ling YH; Andersson BS; Nelson JA
Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
[TBL] [Abstract][Full Text] [Related]
26. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
[TBL] [Abstract][Full Text] [Related]
27. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo.
Holden SA; Teicher BA; Robinson MF; Northey D; Rosowsky A
Cancer Chemother Pharmacol; 1995; 36(2):165-71. PubMed ID: 7767954
[TBL] [Abstract][Full Text] [Related]
28. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay.
Godard T; Deslandes E; Sichel F; Poul JM; Gauduchon P
Mutat Res; 2002 Sep; 520(1-2):47-56. PubMed ID: 12297143
[TBL] [Abstract][Full Text] [Related]
29. [Cytotoxic mechanism and antineoplastic action of etoposide].
Dołega A
Postepy Hig Med Dosw; 1998; 52(1):67-87. PubMed ID: 9608232
[TBL] [Abstract][Full Text] [Related]
30. Characterization of resistance to VP-16 in human leukemic cell line.
Saijo Y; Kumano N; Tokue Y; Satoh K; Oizumi K; Motomiya M
Tohoku J Exp Med; 1989 Dec; 159(4):299-306. PubMed ID: 2633408
[TBL] [Abstract][Full Text] [Related]
31. Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: a new mode of catalytic inhibition.
Jensen LH; Renodon-Corniere A; Wessel I; Langer SW; Søkilde B; Carstensen EV; Sehested M; Jensen PB
Mol Pharmacol; 2002 May; 61(5):1235-43. PubMed ID: 11961142
[TBL] [Abstract][Full Text] [Related]
32. Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide.
Kluza J; Mazinghien R; Irwin H; Hartley JA; Bailly C
Anticancer Drugs; 2006 Feb; 17(2):155-64. PubMed ID: 16428933
[TBL] [Abstract][Full Text] [Related]
33. Auromomycin-induced DNA damage and repair in human leukemic lymphoblasts (CCRF-CEM cells).
Samy TS; Wellham L; Krishan A
Cancer Res; 1986 Feb; 46(2):507-12. PubMed ID: 2934127
[TBL] [Abstract][Full Text] [Related]
34. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
35. Dependence of etoposide-induced cytotoxicity and topoisomerase II-mediated DNA strand breakage on the intracellular ionic environment.
Lawrence TS; Canman CE; Maybaum J; Davis MA
Cancer Res; 1989 Sep; 49(17):4775-9. PubMed ID: 2547516
[TBL] [Abstract][Full Text] [Related]
36. Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Binaschi M; Capranico G; De Isabella P; Mariani M; Supino R; Tinelli S; Zunino F
Int J Cancer; 1990 Feb; 45(2):347-52. PubMed ID: 2154411
[TBL] [Abstract][Full Text] [Related]
37. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
[TBL] [Abstract][Full Text] [Related]
38. Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line.
Patel S; Austin CA; Fisher LM
Anticancer Drug Des; 1990 Feb; 5(1):149-57. PubMed ID: 2156515
[TBL] [Abstract][Full Text] [Related]
39. Effect of cellular ATP depletion on topoisomerase II poisons. Abrogation Of cleavable-complex formation by etoposide but not by amsacrine.
Sorensen M; Sehested M; Jensen PB
Mol Pharmacol; 1999 Mar; 55(3):424-31. PubMed ID: 10051525
[TBL] [Abstract][Full Text] [Related]
40. The bacterial cytolethal distending toxin (CDT) triggers a G2 cell cycle checkpoint in mammalian cells without preliminary induction of DNA strand breaks.
Sert V; Cans C; Tasca C; Bret-Bennis L; Oswald E; Ducommun B; De Rycke J
Oncogene; 1999 Nov; 18(46):6296-304. PubMed ID: 10597228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
